GLP-1 Therapy Linked to 41 Percent Lower Risk of Obesity-Related Cancers: Study
Written By : Dr Kartikeya Kohli
Published On 2026-06-13 03:30 GMT | Update On 2026-06-13 03:30 GMT
Advertisement
Taiwan: In a large propensity-matched cohort study, patients receiving GLP-1 receptor agonists for obesity experienced a 41% lower risk of obesity-associated cancers compared with those managed with diet and exercise alone. Among GLP-1–based therapies, tirzepatide was associated with a substantially greater reduction in cancer risk than semaglutide.
These findings add to a growing body of evidence suggesting that GLP-1–targeted treatments may provide benefits beyond weight loss and glycemic control, potentially contributing to a lower risk of obesity-related malignancies. However, further long-term studies are needed to confirm these observational findings and clarify underlying mechanisms.
The findings were published in Annals of Oncology by A.H.-C. Hsu from the Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, and colleagues.
As obesity-related cancers continue to rise worldwide, interest has grown in whether GLP-1 receptor agonists may offer benefits beyond weight loss. To investigate this, researchers examined the association between GLP-1RA use and obesity-associated cancer risk in obese adults without diabetes.
Using data from the TriNetX database, which includes records from approximately 113 million patients in the United States, the investigators conducted a target trial emulation involving obese, nondiabetic adults with no prior history of obesity-associated cancer between December 2014 and June 2025.
After propensity score matching, the study included 161,798 participants, comprising 80,899 GLP-1RA users and 80,899 matched individuals who received diet or exercise counseling alone. The mean age was 47.2 years, and the median follow-up period was two years.
Key Findings:
- GLP-1 receptor agonist use was associated with a significantly lower incidence of obesity-associated cancers compared with diet and exercise counseling alone.
- Patients receiving GLP-1 receptor agonists had a 41% lower risk of developing any obesity-associated cancer during follow-up.
- The reduced cancer risk associated with GLP-1 receptor agonist use was observed across most patient subgroups evaluated.
- The protective association was seen in both men and women and among individuals with different levels of obesity.
- The association between GLP-1 receptor agonist use and lower cancer risk was not consistently observed among Black participants.
- Additional analyses using inverse probability of treatment weighting confirmed the primary findings, supporting the robustness of the results.
The study is the first to specifically evaluate the association between GLP-1 receptor agonist use and obesity-associated cancer risk in obese adults without diabetes, addressing a gap left by earlier studies that primarily involved diabetic or mixed populations.
The authors concluded that GLP-1RA therapy was associated with a significantly lower short-term incidence of obesity-associated cancers in obese, nondiabetic adults. However, given the observational nature of the study and the median follow-up of only two years, they cautioned that causality cannot be established. Further prospective studies with longer follow-up are needed to confirm these findings and clarify the underlying mechanisms.
Reference:
Hsu, A., Ramirez, P., Chang, Y., Chiang, Y., Santía, M., Meschini, T., Mateo-Kubach, P., Suri, A., & Kamat, A. (2026). GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults. Annals of Oncology. https://doi.org/10.1016/j.annonc.2026.04.013
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.